Home/Pipeline/Cetuximab N01 Injection

Cetuximab N01 Injection

Solid Tumors

Phase 1Active

Key Facts

Indication

Solid Tumors

Phase

Phase 1

Status

Active

Company

Klus Pharma

About Klus Pharma

KLUS Pharma is a U.S.-based biotech subsidiary of China's Kelun-Biotech, leveraging its parent company's integrated R&D and manufacturing platforms to advance a diverse pipeline of oncology and non-oncology biologics. The company has built a robust pipeline with multiple clinical-stage assets, most notably in the competitive ADC space, including TROP2 and HER2-targeting candidates. Its strategy combines internal development with strategic partnerships, such as the recent collaboration with Crescent Biopharma, to maximize the global value of its pipeline. KLUS operates as a key bridge for Kelun-Biotech's ambitions in the U.S. and international markets.

View full company profile

Therapeutic Areas

Oncology Asthma Thromboembolic disorders Autoimmune Disease Cardiovascular Disease

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed
Undisclosed Whole Cell Vaccine Program(s)	Neuvogen	Pre-clinical	Active
SY-5609	Syros Pharmaceuticals	Phase 1/2	Discontinued
Not Specified (TCR Therapy)	T-Cure Bioscience	Phase 1	Active
B7-H3 Program	Ocean Biomedical	Discovery	Active